COMP <GO>
OPRX vs PG // RSI-14 & 200D SMA MOMENTUM
OptimizeRx Corporation (NASDAQ) VS. Procter & Gamble Company (NYSE) • 15-METRIC TALLY: OPRX 6
— PG 7
▲ RSI-14 & 200D SMA MOMENTUM LEADER: OPRX
LAST: $9.32 (-0.53%) • MKT CAP: $176.5M
rsi-technicals
64.3
LAST: $161.57 (+0.61%) • MKT CAP: $372.21B
rsi-technicals
60.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OPRX VS. PG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OPRX | PG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.30% | 51.20% | +16.10 | OPRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.30% | 25.40% | -18.10 | PG | /roic <GO> |
| EV/EBITDA & P/E Valuation | 14.9x | 16.2x | -1.30 | OPRX | /valuation <GO> |
| Free Cash Flow Yield | 10.57% | 3.77% | +6.80 | OPRX | /fcf-yield <GO> |
| Operating Margin | 10.70% | 24.30% | -13.60 | PG | /operating-margins <GO> |
| Net Profit Margin | 4.70% | 19.00% | -14.30 | PG | /net-margins <GO> |
| Revenue Growth (YoY) | 18.80% | 0.30% | +18.50 | OPRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.65% | -2.65 | PG | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.68 | 5.59 | -2.91 | PG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | OPRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 64.3 | 60.3 | +4.00 | OPRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.87 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.9x | 21.7x | +7.20 | PG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $176.5M | $372.21B | -$372.04B | PG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OPRX REV | PG REV | OPRX GROSS % | PG GROSS % | OPRX FCF | PG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $109.4M | $84.28B | 67.3% | 51.2% | $18.7M | $14.04B |
| FY 2024 | $92.1M | $84.04B | 64.5% | 51.4% | $4.8M | $16.52B |
| FY 2023 | $71.5M | $82.01B | — | — | -$7.2M | $13.16B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OPRX // BETA —
PG // BETA 0.87